Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.58 |
| ▸ | CTSK | P43235 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.46 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.45 |
| ▸ | KLK1 | P06870 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.44 |
| ▸ | F7 | P08709 | 2/20 | 0.43 |
| ▸ | F3 | P13726 | 2/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6438355 | 1.00 | CTSS (0.58) | CTSSCTSKCYP3A4CTSBPSMB1 | |
| SCHEMBL6438350 | 1.00 | CTSS (0.58) | CTSSCTSKCYP3A4CTSBPSMB1 | |
| SCHEMBL23013535 | 0.98 | CTSS (0.60) | CTSSCTSKCYP3A4CTSBPSMB1 | |
| SCHEMBL29728739 | 0.98 | CTSS (0.60) | CTSSCTSKCYP3A4CTSBPSMB1 | |
| SCHEMBL23013537 | 0.98 | CTSS (0.60) | CTSSCTSKCYP3A4CTSBPSMB1 | |
| SCHEMBL29481443 | 0.98 | CTSS (0.60) | CTSSCTSKCYP3A4CTSBPSMB1 | |
| SCHEMBL6441367 | 0.85 | CTSS (0.56) | CTSSCTSKCYP3A4PSMB1PSMB8 | |
| SCHEMBL6441360 | 0.85 | CTSS (0.56) | CTSSCTSKCYP3A4PSMB1PSMB8 | |
| SCHEMBL6441362 | 0.85 | CTSS (0.56) | CTSSCTSKCYP3A4PSMB1PSMB8 | |
| SCHEMBL29728757 | 0.83 | CTSS (0.44) | CTSSCTSKCYP3A4CTSBPSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1505062-A1 | Heterocyclic derivatives and their use as antithrombotic agents | Akzo Nobel N.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| US-6432955-B1 | ANTICOAGULANTS | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | CTSS 2510/4885CTSK 3152/4885CYP3A4 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.